{"id":"r-mant","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-MANT likely refers to a rituximab-containing regimen (possibly rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone or similar CHOP-like backbone) used in lymphoma treatment. Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells, leading to antibody-dependent cellular cytotoxicity and direct apoptosis, combined with cytotoxic chemotherapy for enhanced anti-tumor effect.","oneSentence":"R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:07.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi)"}]},"trialDetails":[{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab (R)"],"phase":"phase_3","status":"active","brandName":"R-MANT","genericName":"R-MANT","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies. Used for Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}